Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study

Eva Petkova, R. Todd Ogden, Thaddeus Tarpey, Adam Ciarleglio, Bei Jiang, Zhe Su, Thomas Carmody, Philip Adams, Helena C. Kraemer, Bruce D. Grannemann, Maria A. Oquendo, Ramin Parsey, Myrna Weissman, Patrick J. McGrath, Maurizio Fava, Madhukar H. Trivedi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Antidepressant medications are commonly used to treat depression, but only about 30% of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers for treatment response is largely based on secondary analyses of studies designed to answer primary questions of efficacy, rather than on a planned systematic evaluation of biomarkers for treatment decision. The lack of evidence-based knowledge to guide treatment decisions for patients with depression has lead to the recognition that specially designed studies with the primary objective being to discover biosignatures for optimizing treatment decisions are necessary. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is one such discovery study. Stage 1 of EMBARC is a randomized placebo controlled clinical trial of 8 week duration. A wide array of patient characteristics is collected at baseline, including assessments of brain structure, function and connectivity along with electrophysiological, biological, behavioral and clinical features. This paper reports on the data analytic strategy for discovering biosignatures for treatment response based on Stage 1 of EMBARC.

Original languageEnglish (US)
Pages (from-to)22-30
Number of pages9
JournalContemporary Clinical Trials Communications
Volume6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Antidepressive Agents
Therapeutics
Biomarkers
Clinical Studies
Randomized Controlled Trials
Placebos
Brain

Keywords

  • Combining biomarkers
  • Differential treatment response index
  • Moderator
  • Optimizing treatment decisions
  • Precision medicine

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study. / Petkova, Eva; Ogden, R. Todd; Tarpey, Thaddeus; Ciarleglio, Adam; Jiang, Bei; Su, Zhe; Carmody, Thomas; Adams, Philip; Kraemer, Helena C.; Grannemann, Bruce D.; Oquendo, Maria A.; Parsey, Ramin; Weissman, Myrna; McGrath, Patrick J.; Fava, Maurizio; Trivedi, Madhukar H.

In: Contemporary Clinical Trials Communications, Vol. 6, 01.06.2017, p. 22-30.

Research output: Contribution to journalArticle

Petkova, E, Ogden, RT, Tarpey, T, Ciarleglio, A, Jiang, B, Su, Z, Carmody, T, Adams, P, Kraemer, HC, Grannemann, BD, Oquendo, MA, Parsey, R, Weissman, M, McGrath, PJ, Fava, M & Trivedi, MH 2017, 'Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study', Contemporary Clinical Trials Communications, vol. 6, pp. 22-30. https://doi.org/10.1016/j.conctc.2017.02.007
Petkova, Eva ; Ogden, R. Todd ; Tarpey, Thaddeus ; Ciarleglio, Adam ; Jiang, Bei ; Su, Zhe ; Carmody, Thomas ; Adams, Philip ; Kraemer, Helena C. ; Grannemann, Bruce D. ; Oquendo, Maria A. ; Parsey, Ramin ; Weissman, Myrna ; McGrath, Patrick J. ; Fava, Maurizio ; Trivedi, Madhukar H. / Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study. In: Contemporary Clinical Trials Communications. 2017 ; Vol. 6. pp. 22-30.
@article{99ebaa47d99644119a1c4199820f3b5b,
title = "Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study",
abstract = "Antidepressant medications are commonly used to treat depression, but only about 30{\%} of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers for treatment response is largely based on secondary analyses of studies designed to answer primary questions of efficacy, rather than on a planned systematic evaluation of biomarkers for treatment decision. The lack of evidence-based knowledge to guide treatment decisions for patients with depression has lead to the recognition that specially designed studies with the primary objective being to discover biosignatures for optimizing treatment decisions are necessary. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is one such discovery study. Stage 1 of EMBARC is a randomized placebo controlled clinical trial of 8 week duration. A wide array of patient characteristics is collected at baseline, including assessments of brain structure, function and connectivity along with electrophysiological, biological, behavioral and clinical features. This paper reports on the data analytic strategy for discovering biosignatures for treatment response based on Stage 1 of EMBARC.",
keywords = "Combining biomarkers, Differential treatment response index, Moderator, Optimizing treatment decisions, Precision medicine",
author = "Eva Petkova and Ogden, {R. Todd} and Thaddeus Tarpey and Adam Ciarleglio and Bei Jiang and Zhe Su and Thomas Carmody and Philip Adams and Kraemer, {Helena C.} and Grannemann, {Bruce D.} and Oquendo, {Maria A.} and Ramin Parsey and Myrna Weissman and McGrath, {Patrick J.} and Maurizio Fava and Trivedi, {Madhukar H.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.conctc.2017.02.007",
language = "English (US)",
volume = "6",
pages = "22--30",
journal = "Contemporary Clinical Trials Communications",
issn = "2451-8654",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study

AU - Petkova, Eva

AU - Ogden, R. Todd

AU - Tarpey, Thaddeus

AU - Ciarleglio, Adam

AU - Jiang, Bei

AU - Su, Zhe

AU - Carmody, Thomas

AU - Adams, Philip

AU - Kraemer, Helena C.

AU - Grannemann, Bruce D.

AU - Oquendo, Maria A.

AU - Parsey, Ramin

AU - Weissman, Myrna

AU - McGrath, Patrick J.

AU - Fava, Maurizio

AU - Trivedi, Madhukar H.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Antidepressant medications are commonly used to treat depression, but only about 30% of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers for treatment response is largely based on secondary analyses of studies designed to answer primary questions of efficacy, rather than on a planned systematic evaluation of biomarkers for treatment decision. The lack of evidence-based knowledge to guide treatment decisions for patients with depression has lead to the recognition that specially designed studies with the primary objective being to discover biosignatures for optimizing treatment decisions are necessary. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is one such discovery study. Stage 1 of EMBARC is a randomized placebo controlled clinical trial of 8 week duration. A wide array of patient characteristics is collected at baseline, including assessments of brain structure, function and connectivity along with electrophysiological, biological, behavioral and clinical features. This paper reports on the data analytic strategy for discovering biosignatures for treatment response based on Stage 1 of EMBARC.

AB - Antidepressant medications are commonly used to treat depression, but only about 30% of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers for treatment response is largely based on secondary analyses of studies designed to answer primary questions of efficacy, rather than on a planned systematic evaluation of biomarkers for treatment decision. The lack of evidence-based knowledge to guide treatment decisions for patients with depression has lead to the recognition that specially designed studies with the primary objective being to discover biosignatures for optimizing treatment decisions are necessary. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is one such discovery study. Stage 1 of EMBARC is a randomized placebo controlled clinical trial of 8 week duration. A wide array of patient characteristics is collected at baseline, including assessments of brain structure, function and connectivity along with electrophysiological, biological, behavioral and clinical features. This paper reports on the data analytic strategy for discovering biosignatures for treatment response based on Stage 1 of EMBARC.

KW - Combining biomarkers

KW - Differential treatment response index

KW - Moderator

KW - Optimizing treatment decisions

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85014508995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014508995&partnerID=8YFLogxK

U2 - 10.1016/j.conctc.2017.02.007

DO - 10.1016/j.conctc.2017.02.007

M3 - Article

VL - 6

SP - 22

EP - 30

JO - Contemporary Clinical Trials Communications

JF - Contemporary Clinical Trials Communications

SN - 2451-8654

ER -